Developer docs
API playgroundTry for free, no card

Search company profiles

Revitalist

Full company profile

uuid0000yka

Namestring
Revitalist
Legal namestring
Revitalist
Websiteurl
revitalist.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Revitalist operates a multi-location, direct-to-consumer ketamine therapy and mental health clinic business headquartered in Knoxville, Tennessee, with additional sites in Johnson City, TN and Tampa/Clearwater, FL. The company was founded in 2018 by Kathryn Walker, who holds MSN degrees in both Anesthesia and Psychiatry, and serves patients with treatment-resistant depression, PTSD, anxiety, OCD, bipolar disorder, chronic pain syndromes, suicidal ideation, and co-occurring substance use disorders. Its core clinical offering is IV ketamine infusion therapy, which leverages ketamine's NMDA/glutamate receptor mechanism to produce rapid symptom relief within hours, in contrast to the weeks-to-months onset typical of traditional SSRIs and SNRIs. Revitalist supplements this with Spravato (esketamine nasal spray, FDA-approved 2019 and insurance-reimbursable), Ketamine-Assisted Psychotherapy combining infusions with therapist integration, supervised at-home ketamine therapy, IV vitamin infusions, and a neuropeptide therapy line targeting trauma circuits at the cellular level.

The business runs on a hybrid cash-pay and insurance-reimbursement model: ketamine infusions and adjunct services are paid out-of-pocket or via monthly membership and per-visit plans, while Spravato is billed through participating insurers including Wellpoint. Patient acquisition is driven by content marketing (blog, podcast, social), a free initial assessment funnel, and a dedicated provider referral program for healthcare professionals and first-responder organizations. The company self-reports an 80% success rate across treatment-resistant cases and an 87% profound trauma healing rate among Johnson City PTSD patients, though these are not externally validated. Disclosed financial history shows revenue of approximately $2.07M in 2021 and $4.57M in 2022, funded by roughly $5.14M in combined equity raises, while operating losses remained substantial at approximately -$11M EBITDA in 2022, reflecting heavy reinvestment into clinic buildout, geographic expansion, and new product development.

Short descriptiontext

Revitalist is a multi-location U.S. ketamine therapy clinic operator, founded in 2018 and led by CEO Kathryn Walker, that delivers IV ketamine infusions, Spravato, neuropeptide therapy, and related treatments to patients with treatment-resistant depression, PTSD, chronic pain, and other conditions across clinics in Tennessee and Florida.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKnoxville, United States
HQ citystring
Knoxville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ketamine therapy, mental health treatments, chronic pain management, esketamine treatment, iv vitamin infusions
Industry2 codes
1Outpatient Mental Health Clinics & Counseling Centers
CodeHLAFACAAPrimaryYes
2Outpatient Mental Health & Counseling Clinics
CodeHLAFABACPrimaryNo
NAICS code2 codes
  • Outpatient Mental Health and Substance Abuse Centers62142
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Specialty Outpatient Facilities, Nec8093
Product category
Ketamine Therapy and Mental Health Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Ketamine Infusion Therapy
TypeSubscription Recurring
Description

IV ketamine treatments administered in clinic for mental health and chronic pain conditions. Patients pay per infusion or through treatment packages. Initial series typically involves 6 infusions over 2-3 weeks.

revitalistclinic.com
2Spravato (Esketamine) Treatment
TypeSubscription Recurring
Description

Insurance-covered nasal spray treatment for treatment-resistant depression. Revenue collected through insurance reimbursement and patient co-pays.

revitalistclinic.com
3Vitamin Infusion Therapy
TypeOne Time License
Description

IV vitamin therapy services for wellness, hydration, and nutrient supplementation. Offered as standalone treatments or integrated with ketamine protocols.

revitalistclinic.com
4Neuropeptide Therapy
TypeOne Time License
Description

Cellular-level peptide treatments for stress response regulation and trauma recovery. Offered as specialized treatment protocols.

revitalistclinic.com
5Membership/Package Plans
TypeSubscription Recurring
Description

Monthly membership and pay-as-you-go pricing options providing equitable and accessible care with flexible payment structures.

revitalistclinic.com
6Provider Referrals
TypeProfessional Services
Description

Referral network from healthcare providers sending patients for specialized ketamine and mental health treatments.

revitalistclinic.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
Pricing details3 tiers
1Pay As You Go option for flexible, per-visit payments
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Flexible payment per treatment session without commitment to ongoing plans

revitalistclinic.com
2Monthly Membership plan for consistent care at reduced rates
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly commitment providing same level of care at a price point that suits patient needs

revitalistclinic.com
3Insurance-covered Spravato treatment
ModelSubscriptionBilling cadenceMonthly
Notes

Spravato is covered by insurance for eligible patients with treatment-resistant depression

revitalistclinic.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Revitalist operates multi-location ketamine therapy clinics that administer IV ketamine infusions, Spravato (esketamine) nasal spray, ketamine-assisted psychotherapy, IV vitamin therapy, and neuropeptide therapy. The clinics serve patients suffering from treatment-resistant depression, anxiety, PTSD, OCD, chronic pain syndromes, and suicidal ideation across three locations in Tennessee and Florida. The company also provides supervised at-home ketamine therapy for patients unable to visit a clinic.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80% success rate for ketamine therapy in treatment-resistant conditions
+3 more records
Product overview1 text field

Revitalist Clinic operates a multi-location ketamine therapy practice offering a portfolio of breakthrough mental health and pain treatments. The core offerings include IV Ketamine Therapy (the flagship treatment), Home Ketamine Therapy, and Ketamine Assisted Psychotherapy — all utilizing ketamine's NMDA/glutamate mechanism for rapid neuroplasticity and symptom relief. The company also provides Spravato® (FDA-approved esketamine nasal spray) for treatment-resistant depression, IV Vitamin Infusion Therapy for wellness support, and Neuropeptide Therapy for cellular-level trauma recovery. The clinic treats conditions including depression, anxiety, PTSD, OCD, bipolar disorder, chronic pain, suicidal ideation, and substance abuse across three locations in Tennessee and Florida.

Product and service7 records
1Ketamine Therapy
CategoryKetamine Therapy
Description

IV infusion therapy utilizing FDA-approved ketamine to provide rapid symptom relief for treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, chronic pain, and suicidal ideation by modulating the NMDA/glutamate system and promoting neuroplasticity.

2Home Ketamine Therapy
CategoryKetamine Therapy
Description

Supervised ketamine therapy delivered safely in the patient's own home with medical oversight, providing convenient access for patients unable to travel to clinic locations.

3Ketamine Assisted Psychotherapy
CategoryKetamine Therapy
Description

Combination of ketamine infusion with a trained therapist present during or immediately after sessions to help patients process insights and emotions for enhanced treatment outcomes.

4Spravato (Esketamine)
CategoryMental Health Treatment
Description

FDA-approved nasal spray treatment using esketamine for treatment-resistant depression, covered by insurance and providing rapid symptom improvement for patients who have not responded to conventional antidepressants.

5Vitamin Infusions (IV Vitamin Infusion Therapy)
CategoryWellness Therapy
Description

IV therapy delivering essential nutrients and vitamins directly into the bloodstream for maximum absorption, supporting wellness goals including migraine relief, immune strengthening, energy optimization, and recovery.

6Neuropeptide Therapy
CategoryMental Health Treatment
Description

Peptide treatments operating at the cellular level to regulate stress response, calm hyperactive trauma circuits, and support comprehensive PTSD and mental health recovery.

7Supplements
CategoryWellness Therapy
Description

Nutritional supplements offered to support patient health and complement treatment outcomes.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Telehealth-led ketamine therapy company offering at-home treatments for depression, anxiety, and chronic pain. Overlaps with Revitalist on patient indications and the at-home ketamine service.

TypeDirect peer
Description

DTC ketamine therapy platform offering at-home and clinic-based treatment protocols for mental health; comparable consumer positioning and subscription/membership pricing model.

TypeDirect peer
Description

Independent outpatient ketamine infusion clinic treating depression, PTSD, and chronic pain. Comparable single/regional operator with similar treatment menu and patient mix.

TypeBroad incumbent
Description

Clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. Not a direct service competitor but a leading incumbent shaping the broader ketamine/psychedelic-assisted therapy market.

TypeDirect peer
Description

Operated a network of ketamine-assisted psychotherapy clinics across North America focused on mental health; same patient population, same protocol-based IV ketamine offering, same outpatient clinic model.

TypeRegional player
Description

Multi-location ketamine therapy and interventional psychiatry provider in the Western U.S. Overlapping outpatient ketamine clinic model and similar patient indications, but serves a different regional footprint.

TypeDirect peer
Description

Network of outpatient clinics offering ketamine infusion therapy and other neurotherapies for depression and chronic pain; comparable clinical model and outpatient specialty positioning.

TypeDirect peer
Description

Direct-to-consumer ketamine therapy provider offering at-home and clinic-based treatments for depression, anxiety, and PTSD. Highly comparable in treatment menu, patient positioning, and D2C GTM motion.

TypeBroad incumbent
Description

Manufacturer of Spravato (esketamine), the FDA-approved nasal spray Revitalist administers. A large incumbent that defines the REMS-constrained treatment environment and shapes payer policy for ketamine-assisted care.

TypeDirect peer
Description

Telehealth and clinic-based ketamine therapy provider for treatment-resistant depression, anxiety, and PTSD; directly comparable outpatient ketamine-assisted psychotherapy service line.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Revitalist

Ketamine Therapy and Mental Health Servicesrevitalist.com

Revitalist is a multi-location U.S. ketamine therapy clinic operator, founded in 2018 and led by CEO Kathryn Walker, that delivers IV ketamine infusions, Spravato, neuropeptide therapy, and related treatments to patients with treatment-resistant depression, PTSD, chronic pain, and other conditions across clinics in Tennessee and Florida.

What Revitalist does

Revitalist operates a multi-location, direct-to-consumer ketamine therapy and mental health clinic business headquartered in Knoxville, Tennessee, with additional sites in Johnson City, TN and Tampa/Clearwater, FL. The company was founded in 2018 by Kathryn Walker, who holds MSN degrees in both Anesthesia and Psychiatry, and serves patients with treatment-resistant depression, PTSD, anxiety, OCD, bipolar disorder, chronic pain syndromes, suicidal ideation, and co-occurring substance use disorders. Its core clinical offering is IV ketamine infusion therapy, which leverages ketamine's NMDA/glutamate receptor mechanism to produce rapid symptom relief within hours, in contrast to the weeks-to-months onset typical of traditional SSRIs and SNRIs. Revitalist supplements this with Spravato (esketamine nasal spray, FDA-approved 2019 and insurance-reimbursable), Ketamine-Assisted Psychotherapy combining infusions with therapist integration, supervised at-home ketamine therapy, IV vitamin infusions, and a neuropeptide therapy line targeting trauma circuits at the cellular level.

The business runs on a hybrid cash-pay and insurance-reimbursement model: ketamine infusions and adjunct services are paid out-of-pocket or via monthly membership and per-visit plans, while Spravato is billed through participating insurers including Wellpoint. Patient acquisition is driven by content marketing (blog, podcast, social), a free initial assessment funnel, and a dedicated provider referral program for healthcare professionals and first-responder organizations. The company self-reports an 80% success rate across treatment-resistant cases and an 87% profound trauma healing rate among Johnson City PTSD patients, though these are not externally validated. Disclosed financial history shows revenue of approximately $2.07M in 2021 and $4.57M in 2022, funded by roughly $5.14M in combined equity raises, while operating losses remained substantial at approximately -$11M EBITDA in 2022, reflecting heavy reinvestment into clinic buildout, geographic expansion, and new product development.

Revitalist firmographics

Firmographics
Name
Revitalist
Legal name
Revitalist
Website
https://revitalist.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Revitalist is a multi-location U.S. ketamine therapy clinic operator, founded in 2018 and led by CEO Kathryn Walker, that delivers IV ketamine infusions, Spravato, neuropeptide therapy, and related treatments to patients with treatment-resistant depression, PTSD, chronic pain, and other conditions across clinics in Tennessee and Florida.
Ownership category
akta.pro rank

Revitalist industry classification

Industry
Product category
Ketamine Therapy and Mental Health Services
NAICS
Outpatient Mental Health and Substance Abuse Centers (62142), Offices of Physicians, Mental Health Specialists (621112)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)
akta.pro primary industry
Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)
akta.pro secondary industry
Outpatient Mental Health & Counseling Clinics (HLAFABAC)

Keywords

  • Ketamine therapy
  • Mental health treatments
  • Chronic pain management
  • Esketamine treatment
  • Iv vitamin infusions

Where Revitalist is headquartered

Location

Headquarters

HQ city
Knoxville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Revitalist business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

  1. Ketamine Infusion Therapy: IV ketamine treatments administered in clinic for mental health and chronic pain conditions. Patients pay per infusion or through treatment packages. Initial series typically involves 6 infusions over 2-3 weeks.
  2. Spravato (Esketamine) Treatment: Insurance-covered nasal spray treatment for treatment-resistant depression. Revenue collected through insurance reimbursement and patient co-pays.
  3. Vitamin Infusion Therapy: IV vitamin therapy services for wellness, hydration, and nutrient supplementation. Offered as standalone treatments or integrated with ketamine protocols.
  4. Neuropeptide Therapy: Cellular-level peptide treatments for stress response regulation and trauma recovery. Offered as specialized treatment protocols.
  5. Membership/Package Plans: Monthly membership and pay-as-you-go pricing options providing equitable and accessible care with flexible payment structures.
  6. Provider Referrals: Referral network from healthcare providers sending patients for specialized ketamine and mental health treatments.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPay As You Go option for flexible, per-visit payments
SubscriptionMonthlyMonthly Membership plan for consistent care at reduced rates
SubscriptionMonthlyInsurance-covered Spravato treatment

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Revitalist product offering

Product offering

Core offering

Revitalist operates multi-location ketamine therapy clinics that administer IV ketamine infusions, Spravato (esketamine) nasal spray, ketamine-assisted psychotherapy, IV vitamin therapy, and neuropeptide therapy. The clinics serve patients suffering from treatment-resistant depression, anxiety, PTSD, OCD, chronic pain syndromes, and suicidal ideation across three locations in Tennessee and Florida. The company also provides supervised at-home ketamine therapy for patients unable to visit a clinic.

Product overview

Revitalist Clinic operates a multi-location ketamine therapy practice offering a portfolio of breakthrough mental health and pain treatments. The core offerings include IV Ketamine Therapy (the flagship treatment), Home Ketamine Therapy, and Ketamine Assisted Psychotherapy — all utilizing ketamine's NMDA/glutamate mechanism for rapid neuroplasticity and symptom relief. The company also provides Spravato® (FDA-approved esketamine nasal spray) for treatment-resistant depression, IV Vitamin Infusion Therapy for wellness support, and Neuropeptide Therapy for cellular-level trauma recovery. The clinic treats conditions including depression, anxiety, PTSD, OCD, bipolar disorder, chronic pain, suicidal ideation, and substance abuse across three locations in Tennessee and Florida.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ketamine Therapy IV infusion therapy utilizing FDA-approved ketamine to provide rapid symptom relief for treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, chronic pain, and suicidal ideation by modulating the NMDA/glutamate system and promoting neuroplasticity.
  • Home Ketamine Therapy Supervised ketamine therapy delivered safely in the patient's own home with medical oversight, providing convenient access for patients unable to travel to clinic locations.
  • Ketamine Assisted Psychotherapy Combination of ketamine infusion with a trained therapist present during or immediately after sessions to help patients process insights and emotions for enhanced treatment outcomes.
  • Spravato (Esketamine) FDA-approved nasal spray treatment using esketamine for treatment-resistant depression, covered by insurance and providing rapid symptom improvement for patients who have not responded to conventional antidepressants.
  • Vitamin Infusions (IV Vitamin Infusion Therapy) IV therapy delivering essential nutrients and vitamins directly into the bloodstream for maximum absorption, supporting wellness goals including migraine relief, immune strengthening, energy optimization, and recovery.
  • Neuropeptide Therapy Peptide treatments operating at the cellular level to regulate stress response, calm hyperactive trauma circuits, and support comprehensive PTSD and mental health recovery.
  • Supplements Nutritional supplements offered to support patient health and complement treatment outcomes.

Quantifiable outcome

  • 80% success rate for ketamine therapy in treatment-resistant conditions
  • +3 more outcomes

Companies that use Revitalist

Customer profile

Named customers7 records

Segments6 records

Ideal customer profiles3 records

Revitalist technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Revitalist partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Revitalist competitors and assessment

Company assessment

Direct peers

  • KetaMD: Telehealth-led ketamine therapy company offering at-home treatments for depression, anxiety, and chronic pain. Overlaps with Revitalist on patient indications and the at-home ketamine service.
  • Better U (formerly BetterHelp-affiliated ketamine programs): DTC ketamine therapy platform offering at-home and clinic-based treatment protocols for mental health; comparable consumer positioning and subscription/membership pricing model.
  • Austin Ketamine Clinic: Independent outpatient ketamine infusion clinic treating depression, PTSD, and chronic pain. Comparable single/regional operator with similar treatment menu and patient mix.
  • Field Trip Health: Operated a network of ketamine-assisted psychotherapy clinics across North America focused on mental health; same patient population, same protocol-based IV ketamine offering, same outpatient clinic model.
  • Actify Neurotherapies: Network of outpatient clinics offering ketamine infusion therapy and other neurotherapies for depression and chronic pain; comparable clinical model and outpatient specialty positioning.
  • Mindbloom: Direct-to-consumer ketamine therapy provider offering at-home and clinic-based treatments for depression, anxiety, and PTSD. Highly comparable in treatment menu, patient positioning, and D2C GTM motion.
  • Nue Life Health: Telehealth and clinic-based ketamine therapy provider for treatment-resistant depression, anxiety, and PTSD; directly comparable outpatient ketamine-assisted psychotherapy service line.

Broad incumbents

  • Compass Pathways: Clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. Not a direct service competitor but a leading incumbent shaping the broader ketamine/psychedelic-assisted therapy market.
  • Janssen Pharmaceuticals (Spravato / esketamine): Manufacturer of Spravato (esketamine), the FDA-approved nasal spray Revitalist administers. A large incumbent that defines the REMS-constrained treatment environment and shapes payer policy for ketamine-assisted care.

Regional players

  • Cedar Psychiatry: Multi-location ketamine therapy and interventional psychiatry provider in the Western U.S. Overlapping outpatient ketamine clinic model and similar patient indications, but serves a different regional footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revitalist social profiles

Digital presence

Revitalist financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Revitalist leadership team

Management profile

Number of profiles

Profiles1 record

Revitalist funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Revitalist M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revitalist

What does Revitalist do?

Revitalist operates multi-location ketamine therapy clinics that administer IV ketamine infusions, Spravato (esketamine) nasal spray, ketamine-assisted psychotherapy, IV vitamin therapy, and neuropeptide therapy. The clinics serve patients suffering from treatment-resistant depression, anxiety, PTSD, OCD, chronic pain syndromes, and suicidal ideation across three locations in Tennessee and Florida. The company also provides supervised at-home ketamine therapy for patients unable to visit a clinic.

Is Revitalist a public or private company?

Revitalist is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Revitalist founded?

Revitalist was founded in 2018. It employs 11 to 50 people.

Where is Revitalist based?

Revitalist is headquartered in Knoxville, United States, in the North America region.

How does Revitalist make money?

Six revenue lines are on record. Ketamine Infusion Therapy is the primary driver. The others are spravato (Esketamine) Treatment, vitamin Infusion Therapy, neuropeptide Therapy, membership/Package Plans and provider Referrals.

Who are Revitalist's main competitors?

Direct peers on record are KetaMD, Better U (formerly BetterHelp-affiliated ketamine programs), Austin Ketamine Clinic, Field Trip Health, Actify Neurotherapies, Mindbloom and Nue Life Health. Broad incumbents are Compass Pathways and Janssen Pharmaceuticals (Spravato / esketamine). Cedar Psychiatry is listed as a regional player.

Does Revitalist have an API?

No public API is recorded for Revitalist.

What industry is Revitalist in?

Revitalist's product category is Ketamine Therapy and Mental Health Services. Its primary akta.pro industry code is HLAFACAA, Outpatient Mental Health Clinics & Counseling Centers, with a secondary code of HLAFABAC, Outpatient Mental Health & Counseling Clinics. Its NAICS code is 62142 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GrowthmarketreportsKetamine Clinics Market Size to Hit USD 8.13 Billion by 2034The global ketamine clinics market reached USD 2.6 billion in 2025 and is projected to grow at a compound annual growth rate of 13.5% to reach USD 8.1 billion by 2034, driven by rising prevalence of treatment-resistant depression, increasing mental health awareness, and expanding insurance reimbursement for ketamine-based therapies. North America dominates the market with approximately 46.5% global revenue share in 2025, followed by Europe at 25.0% and Asia Pacific at 18.5%. The competitive landscape includes specialized clinic operators such as Mindbloom, Ember Health, Ketamine Clinics Los Angeles, and Revitalist Clinic, alongside broader mental health providers expanding into ketamine therapy services.GlobeNewswireSix Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health CareKathryn Walker, founder of Revitalist, developed Kate NeuroPsych, an AI bot for ketamine and psychedelic treatment intake. She plans to open multiple clinics in 2024 and secure over 100 licensing agreements by 2025. Walker also developed a validated mental health scale and aims to normalize psychedelics in care.Business Wire BlogRevitalist Closes First Tranche of Private Placement Offering, Grant of Restricted Share Units and Announces Anticipated Cease Trade OrderRevitalist Lifestyle and Wellness Ltd. closed the first tranche of a private placement offering, raising $1,139,500 from the sale of 56,975,000 units, while simultaneously announcing it will miss its May 1, 2023 filing deadline for annual financial statements. Consequently, the company anticipates a cease trade order on its securities under National Policy 11-207 due to this failure to file. The company intends to use the proceeds for operations and general working capital, with an expectation to finalize filings by June 15, 2023.PR NewswireMYND Executes LOI to Enter into a Clinical Research Collaboration with RevitalistMYND Life Sciences' wholly-owned subsidiary MYND Diagnostics has executed a binding letter of intent with Revitalist Lifestyle and Wellness to conduct clinical research using MYND's proprietary anti-inflammatory peptide (MAP) biomarker for mental illness diagnosis. The collaboration will leverage Revitalist's network of over 2,300 patients across U.S. clinics, with initial clinical trials focused on COVID-19 survivors experiencing post-infection mental health symptoms known as "Brain Fog." The parties anticipate submitting MAP biomarker data to the U.S. FDA for approval in Q2 2022, with MYND expecting to generate near-term revenue through this research and development partnership.